Academic Journals Database
Disseminating quality controlled scientific knowledge

Endoscopic retrograde cholangiopancreatography associated pancreatitis: A 15-year review

ADD TO MY LIST
 
Author(s): Kevin E Woods | Field F Willingham

Journal: World Journal of Gastrointestinal Endoscopy
ISSN 1948-5190

Volume: 2;
Issue: 5;
Start page: 165;
Date: 2010;
Original page

Keywords: Cholangiopancreatography endoscopic retrograde | Adverse effects | Pancreatitis | Prevention and control/therapy | Risk assessment | Risk factors | Ampulla of vater | Sphincter of oddi | Humans

ABSTRACT
The aim of this article is to review the literature regarding post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. We searched for and evaluated all articles describing the diagnosis, epidemiology, pathophysiology, morbidity, mortality and prevention of post-ERCP pancreatitis (PEP) in adult patients using the PubMed database. Search terms included endoscopic retrograde cholangiopancreatography, pancreatitis, ampulla of vater, endoscopic sphincterotomy, balloon dilatation, cholangiography, adverse events, standards and utilization. We limited our review of articles to those published between January 1, 1994 and August 15, 2009 regarding human adults and written in the English language. Publications from the reference sections were reviewed and included if they were salient and fell into the time period of interest. Between the dates queried, seventeen large (> 500 patients) prospective and four large retrospective trials were conducted. PEP occurred in 1%-15% in the prospective trials and in 1%-4% in the retrospective trials. PEP was also reduced with pancreatic duct stent placement and outcomes were improved with endoscopic sphincterotomy compared to balloon sphincter dilation in the setting of choledocholithiasis. Approximately 34 pharmacologic agents have been evaluated for the prevention of PEP over the last fifteen years in 63 trials. Although 22 of 63 trials published during our period of review suggested a reduction in PEP, no pharmacologic therapy has been widely accepted in clinical use in decreasing the development of PEP. In conclusion, PEP is a well-recognized complication of ERCP. Medical treatment for prevention has been disappointing. Proper patient selection and pancreatic duct stenting have been shown to reduce the complication rate in randomized clinical trials.
Affiliate Program     

Tango Rapperswil
Tango Rapperswil